Benzinga | Aug 9, 2021 04:04PM EDT

Halozyme Therapeutics Q2 Adj. EPS $0.66 Beats $0.40 Estimate, Sales $136.50M Beat $103.16M Estimate; Raises Guidance

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.40 by 65 percent. This is a 247.37 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $136.50 million which beat the analyst consensus estimate of $103.16 million by 32.32 percent. This is a 147.19 percent increase over sales of $55.22 million the same period last year.